Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score–Matched Cohort Study

Objective We aimed to evaluate the comparative risk of hospitalized infection among patients with rheumatoid arthritis ( RA ) who initiated abatacept versus a tumor necrosis factor inhibitor ( TNF i). Methods Using claims data from Truven MarketScan database (2006–2015), we identified patients with RA ages ≥18 years with ≥2 RA diagnoses who initiated treatment with abatacept or a TNF i. The primary outcome was a composite end point of any...